AMF siRNA treatment of keloid through inhibition signaling pathway of RhoA/ROCK1

Tuan, 1996, Elevated levels of plasminogen activator inhibitor-1 may account for the altered fibrinolysis by keloid fibroblasts, J Invest Dermatol, 106, 1007, 10.1111/1523-1747.ep12338552 Slemp, 2006, Keloids and scars: a review of keloids and scars, their pathogenesis, risk factors, and management, Curr Opin Pediatr, 18, 396, 10.1097/01.mop.0000236389.41462.ef Ogawa, 2008, Keloids as a serious disease such as malignancy, Plast Reconstr Surg, 122, 993, 10.1097/PRS.0b013e31818120a0 Yao, 2018, Tumor suppressive role of miR-1224-5p in keloid proliferation, apoptosis and invasion via the TGF-beta 1/Smad 3 signaling pathway, Biochem Biophys Res Commun, 495, 713, 10.1016/j.bbrc.2017.10.070 Taheri, 2017, Outcomes of surgical excision and brachytherapy in intractable keloids, World J Plast Surg, 6, 280 Bijlard, 2018, Intralesional cryotherapy versus excision with corticosteroid injections or brachytherapy for keloid treatment: randomised controlled trials, J Plast Reconstr Aesthetic Surg, 71, 847, 10.1016/j.bjps.2018.01.033 Ud-Din, 2013, Strategic management of keloid disease in ethnic skin: a structured approach supported by the emerging literature, Br J Dermatol, 3, 71, 10.1111/bjd.12588 Al-Attar, 2006, Keloid pathogenesis and treatment, Plast Reconstr Surg, 117, 286, 10.1097/01.prs.0000195073.73580.46 Tsutsumi, 2002, Activation of small GTPase Rho is required for autocrine motility factor signaling, Cancer Res, 62, 4484 Liotta, 1986, Tumor cell autocrine motility factor, Proc Natl Acad Sci USA, 83, 3302, 10.1073/pnas.83.10.3302 Endo, 2006, Prognostic value of cell motility activation factors in patients with tongue squamous cell carcinoma, Hum Pathol, 37, 1111, 10.1016/j.humpath.2006.03.020 Jiang, 2006, Expression of autocrine motility factor (AMF) and its receptor, AMFR, in human breast cancer, J Histochem Cytochem, 54, 231, 10.1369/jhc.5A6785.2005 Wang, 2007, Elevated expression of autocrine motility factor receptor correlates with overexpression of RhoC and indicates poor prognosis in hepatocellular carcinoma, Dig Dis Sci, 52, 770, 10.1007/s10620-006-9479-4 Funasaka, 2005, Regulation of phosphoglucose isomerase/autocrine motility factor expression by hypoxia, FASEB J, 19, 1422, 10.1096/fj.05-3699com Tanaka, 2006, Nuclear Rho kinase, Rock2, targets p300 acetyltransferase, J Biol Chem, 281, 15320, 10.1074/jbc.M510954200 Wang, 2002, RhoA-mediated Ca2+ sensitization in erectile function, J Biol Chem, 277, 30614, 10.1074/jbc.M204262200 van Nieuw Amerongen, 2003, Involvement of RhoA/Rho kinase signaling in VEGF-induced endothelial cell migration and angiogenesis in vitro, Arterioscler Thromb Vasc Biol, 23, 211, 10.1161/01.ATV.0000054198.68894.88 Qvigstad, 2005, Dual serotonergic regulation of ventricular contractile force through 5-HT2A and 5-HT4 receptors induced in the acute failing heart, Circ Res, 97, 268, 10.1161/01.RES.0000176970.22603.8d Han, 2018, RNA interference to knock down gene expression, Meth Mol Biol, 1706, 293, 10.1007/978-1-4939-7471-9_16 Nygren, 2005, Targeted drugs in metastatic colorectal cancer with special emphasis on guidelines for the use of bevacizumab and cetuximab: an Acta Oncologica expert report, Acta Oncol, 44, 203, 10.1080/02841860510029798 ter Brake, 2009, Evaluation of safety and efficacy of RNAi against HIV-1 in the human immune system (Rag-2(-/-)gammac(-/-)) mouse model, Gene Ther, 16, 148, 10.1038/gt.2008.124 Das, 2004, Human immunodeficiency virus type 1 escapes from RNA interference-mediated inhibition, J Virol, 78, 2601, 10.1128/JVI.78.5.2601-2605.2004 Judge, 2009, Confirming the RNAi-mediated mechanism of action of siRNA-based cancer therapeutics in mice, J Clin Invest, 119, 661, 10.1172/JCI37515 Zhang, 2014, Increased periostin expression affects the proliferation, collagen synthesis, migration and invasion of keloid fibroblasts under hypoxic conditions, Int J Mol Med, 34, 253, 10.3892/ijmm.2014.1760 Varmeh, 2011, Cellular senescence as a possible mechanism for halting progression of keloid lesions, Genes Cancer, 2, 1061, 10.1177/1947601912440877 Butler, 2008, Current progress in keloid research and treatment, J Am Coll Surg, 206, 731, 10.1016/j.jamcollsurg.2007.12.001 Jumper, 2017, A role for Neuregulin-1 in promoting keloid fibroblast migration via ErbB2-mediated signaling, Acta Derm Venereol, 97, 675, 10.2340/00015555-2587 Jurzak, 2014, Evaluation of genistein ability to modulate CTGF mRNA/protein expression, genes expression of TGFbeta isoforms and expression of selected genes regulating cell cycle in keloid fibroblasts in vitro, Acta Pol Pharm, 71, 972 Noishiki, 2017, Endothelial dysfunction may promote keloid growth, Wound Repair Regen, 25, 976, 10.1111/wrr.12601 Feng, 2017, miR-141-3p inhibits fibroblast proliferation and migration by targeting GAB1 in keloids, Biochem Biophys Res Commun, 490, 302, 10.1016/j.bbrc.2017.06.040 Yun, 2015, Heat shock protein 90 inhibitor (17-AAG) induces apoptosis and decreases cell migration/motility of keloid fibroblasts, Plast Reconstr Surg, 136, 44e, 10.1097/PRS.0000000000001362 Euer, 2002, Identification of genes associated with metastasis of mammary carcinoma in metastatic versus non-metastatic cell lines, Anticancer Res, 22, 733 Ridley, 1992, The small GTP-binding protein rac regulates growth factor-induced membrane ruffling, Cell, 70, 401, 10.1016/0092-8674(92)90164-8 Wang, 2018, A novel therapeutic strategy for cartilage diseases based on lipid nanoparticle-RNAi delivery system, Int J Nanomed, 13617 Stewart, 2011, A stable producer cell line for the manufacture of a lentiviral vector for gene therapy of Parkinson's disease, Hum Gene Ther, 22, 357, 10.1089/hum.2010.142 Zheng, 2009, Downregulation of lentivirus-mediated ILK RNAi on tractional force generation in human retinal Muller cells, Acta Pharmacol Sin, 30, 1625, 10.1038/aps.2009.154